Next Post

Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights |

Related Posts:Managers, What Are You Doing About Change Exhaustion? Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment underway in HAE CHAPTER-1, proof-of-concept Phase 2 prophylactic study using PHVS416 for the prevention of HAE attacks; top-line data […]